Induction of Mixed Hemopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post Transplant in Immunosuppression w/CSA & Mycophenolate Mofetil

Post Transplant in Immunosuppression w/CSA & Mycophenolate Mofetil Clinical Trial

Official title:

Induction of Mixed Hemopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post Transplant in Immunosuppression w/CSA & Mycophenolate Mofetil

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00531635
• Other study ID #: RAC#2001-051
• Status: Recruiting
• Phase: Phase 1
• First received: September 17, 2007
• Last updated: December 11, 2011
• Start date: July 2002
• Est. completion date: June 2012

Study information

• Verified date: December 2011
• Source: King Faisal Specialist Hospital & Research Center
• Contact: Mahmoud AlJurf, MD
• Phone: 966-1-4647272
• Email: maljurf[@]kfshrc.edu.sa
• Is FDA regulated: No
• Health authority: ORA, KFSH&RC: Saudi Arabia
• Study type: Interventional

Clinical Trial Summary

Induction of mixed hemopoietic chimerism in patients using Fludarabine, Low Dose TBI, PBSC Infusion and post transplant in immunosuppression w/CSA & Mycophenolate Mofetil

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 350
• Est. completion date: June 2012
• Est. primary completion date: June 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Patients receiving Fludarabine, Low Dose TBI, PBSC Infusion and post transplant in immunosuppression w/CSA & Mycophenolate Mofetil.

Exclusion Criteria:

• Uncontrolled major medical illnesses

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Post Transplant in Immunosuppression w/CSA & Mycophenolate Mofetil

Intervention

Drug:
• Mycophenolate Mofetil
Induction of Mixed Hemopoietic Chimerism in Patients Using Mycophenolate Mofetil

Locations

Country	Name	City	State
Saudi Arabia	KFSH&RC	Riyadh

Sponsors (1)

Lead Sponsor	Collaborator
King Faisal Specialist Hospital & Research Center

Country where clinical trial is conducted

Saudi Arabia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy		2001-2012	No